SCHEDULE: Vanguard Discloses 5.03% Stake in Nurix Therapeutics

Vanguard Capital Management has reported beneficial ownership of over 5.03% of Nurix Therapeutics Inc. common stock as of June 30, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 5,202,025 shares of Nurix Therapeutics Inc. common stock.
• This holding represents 5.03% of the total class of securities.
• The filing indicates Vanguard has sole voting power over 706,496 shares and sole dispositive power over 5,202,025 shares.
• The reporting date for this ownership stake is June 30, 2026.
• The filing is made under Schedule 13G, indicating it's an informational filing by a passive investor.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates a major institutional investor has taken a notable passive stake, suggesting some level of confidence in the company's prospects.

Positives

• Vanguard's investment signifies confidence from a major institutional investor in Nurix Therapeutics.
• A significant stake held by a large asset manager can potentially lead to increased liquidity and market visibility for the stock.

Negatives

• The filing does not contain any negative financial or operational information about Nurix Therapeutics itself, as it is a disclosure of ownership by Vanguard.

Risks

• As a Schedule 13G filing, it indicates a passive investment. However, any significant shift in Vanguard's holdings could impact the stock price.
• The filing does not detail specific risks related to Nurix Therapeutics' business operations or future prospects.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Nurix Therapeutics.

Management Comments

• Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• No one other person's interest in the securities reported herein is more than 5%.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by large asset managers like Vanguard often signal institutional belief in a company's long-term potential, particularly in the biotechnology sector where innovation and pipeline development are key drivers.

Stakeholder Impact

• Shareholders may see increased confidence due to Vanguard's investment.
• The market may interpret this as a positive signal for Nurix Therapeutics' future performance.

Next Steps

• Vanguard will continue to monitor its investment in Nurix Therapeutics.
• Nurix Therapeutics will continue its business operations and development activities.

Key Dates

Recommendation

This filing is a passive ownership disclosure by a major institutional investor and does not provide new operational or financial performance data for Nurix Therapeutics. While Vanguard's investment is a positive signal, it does not warrant a change in investment strategy without further company-specific performance updates.

Keywords

Nurix Therapeutics, Vanguard, Schedule 13G, Institutional Investor, Biotechnology, Shareholder Disclosure, Common Stock, Ownership Stake